SHORT PRESENTATIONS and POSTERS

- **1.Use of the Gyros Gyrolab xP System to Support High-throughput AAV Sample Testing**. Charlotte Corkhill, Paul Young, Pharmaron, UK.
- **2.Flux sampling suggests metabolic signatures of high antibody-producing CHO cells.** <u>Kate Meeson</u>, Jean Marc Schwartz, Magnus Rattray, University of Manchester; Leon P Pybus, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
- **3.**Integrating industry leading datasets with Genome-scale metabolic models to direct CHO cell line engineering. Ben Strain, Cleo Kontoravdi, Imperial College London; Holly Corrigall, Pavlos Kotidis, GSK, Stevenage, UK.
- **4.**Chloroplast engineering in the green alga Chlamydomonas for production of novel recombinant products. Luyao Yang, Saul Purton; University College London, UK.
- **5.Deciphering molecular drivers of lactate metabolic shift in mammalian cell cultures.** Mauro Torres, Ellie Hawke, Andrew Hayes, Alan J Dickson, University of Manchester; Robyn Hoare, Rachel Scholey, Leon P Pybus, Alison Young, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
- **6.Rationalising mAb candidate screening with a single holistic developability parameter**. Leon F Willis, William Davis Birch, David Westhead, Nikil Kapur, Sheena Radford, David Brockwell, University of Leeds; Isabelle Trayton, Janet Saunders, Maria Bruque, Katie Day, Nicholas Bond, Paul Devine, Christopher Lloyd, Nicholas Darton, AstraZeneca, UK.
- **7.Biomanufacturing and formulation of magnetosome cocktails for biomedical applications.** Alfred <u>Fernández-Castané</u>, Hong Li, Moritz Ebeler, Matthias Franzreb, Tim W. Overton, Owen R.T. Thomas, Aston University.
- **8.**Development of a high-throughput DWP based transfection platform using LONZA's GS PiggyBac technology. James Harvey, Yukti Kataria, <u>Titash Sen</u>, Lonza, UK.
- **9.Investigating Interactions Between Lipopolysaccharide and Monoclonal Antibodies Using Novel Differential Fluorination and 19F NMR.** James Budge, University of Kent.
- **10.**Generating a high-producing clonal CHO population using Amperia for IgG titre analysis. Matthew Reaney, Zeynep Betts, Alan Dickson, University of Manchester; Jon Dempsey, Pathway Biopharma Ltd.
- **11.**Characterization of Liposome Filtration Fouling: Impact of Pressure Variations on Sterile Filtration Performance. Hercules Argyropoulos, Daniel G. Bracewell, Thomas F. Johnson, UCL; Nigel Jackson, Kalliopi Zourna, Cytiva UK.
- **12.A** hybrid stoichiometric/data-driven approach to improve intracellular flux predictions. Morrissey J, Barberi G, Facco P, Strain B Kontoravdi C, Imperial College London, UK.
- **13.Cell-Free DNA Amplification for Genomic Medicine Horses for Courses.** Priya Srivastava, Daniel G. Bracewell, Department of Biochemical Engineering, UCL; John Welsh, Cytiva Europe Limited, UK.
- **14.**Synthetic biology approaches to achieving improved payload-genome upload for AAV capsids. <u>Tina Chen</u>, Robert Whitfield, Darren Nesbeth, University College London, UK.
- **15.Development of a high-throughput DWP based transfection platform using LONZA's GS PiggyBac technology.** James Harvey, <u>Yukti Kataria</u>, Titash Sen, R&D Lonza Biologics, UK.

- **16.**Integrating Kinetic Modelling with Process Measurements for Cross-Cell Line State Estimation in CHO Cell Culture. <u>Luxi Yu</u>, Ehecatl Antonio del Río Chanona, Cleo Kontoravdi, Department of Chemical Engineering, Imperial College London, UK.
- **17.**On Electromagnetic Stimulation in Biomanufacturing Optimisation Using Fluorescent Reporters as a **Proxy for Productivity.** Afra Alkatheeri, Alistair Elfick, School of Engineering, University of Edinburgh.
- **18.** Unravelling AAV production biology by innovative proteomic approaches. A Sergijenko, D Marginean, E Zucchelli, R Esse, S Martin, HY Lin, ML Tiburcio, V Di Cerbo Cell and Gene Therapy Catapult, London.
- **19.**Multiomics time-course profiling of HEK293 cell lines producing AAV uncovers novel pathways for cell line engineering. Ruben Esse, Cell and Gene Therapy Catapult, London.
- **20.**Automatic Raman based feedback control in high throughput small scale model. Mohamed Abdikarim, Alaia Maxwell, Sneha Arora, Deniz Demirhan, Andrew Dean, Anita Dabek, Lonza Biologics plc., Slough, UK.
- **21.Optimising Bispecific Antibody Production using Revvity's Biotherapeutic Workflow Solutions.**<u>Catherine Ingham</u>, Tanaya Surve, Ana Rebocho, Elena Tuccori, Delphine Cougot, Revvity, Cambridge, UK; Jenna Rutber, Sophia Esch, Anubhav Tripathi, Center for Biomedical Engineering, Brown University, RI, USA.
- **22.**Targeting glycolytic regulator PFKFB3 arrests cell growth and reduces cell specific glucose consumption optimising continuous CHO cell culture for a more sustainable perfusion bioprocess. William Smith, Mauro Torres, Alan Dickson, University of Manchester; John Raven, Leon Pybus, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
- **23.**One-step vector assembly platform for rapid production enhancement of multispecific antibodies. Alice Seleiro, Changhavi Ragurajan, Tejal Bhure, Stephen Jaffé, Michael Anbar. Lonza, Cambridge, UK.
- **24.**Engineering CHO Cell Lines to Integrate Transcription Factors Using CRISPR-Cas12i2 for Enhanced Productivity. Vivek Krishnamoorthy, Roshini Pattem, Harry Allsopp, <u>Isabel Whang Zhou</u>, Keerthi Chathoth, Marc Feary, Bernadette Sweeney, Lonza Biologics, Cambridge, UK.
- **25.**High-yield vesicle-packaged recombinant protein production from E. coli. Tara Eastwood, Karen Baker, Bree Streather, Nyasha Allen, Lin Wang, Stanley Botchway, Ian Brown, Jennifer Hiscock, Christopher Lennon, Daniel P Mulvihill, University of Kent, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
- **26.**Investigating Interactions Between Lipopolysaccharide and Monoclonal Antibodies Using Novel Differential Fluorination and 19F NMR. Amy Gorman, Alexander P. Golovanov, The University of Manchester; Stephanie Moore, BioPharmaceuticals Development, R&D, AstraZeneca, Cambridge, UK.
- **27.HEK293** cell line engineering using CRISPR editing techniques for improved AAV2 production. A Sergijenko, HY Lin, G Naso, R Esse, E Zucchelli, V Di Cerbo. Cell and Gene Therapy Catapult, London.



























